RxDoctor Payments Data

Donald Martin, MD

Gastroenterology · Overland Park, KSNPI 1205923109

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 289 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 33.2% of the total. 2025 is the largest year on record at $2,022, more than ten times the $121 reported in 2019.

$4,511in general payments, 2019–2025

Across 289 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$421
  • Lilly USA, LLC$399
  • Bristol Myers Squibb$384
  • Pfizer$222
  • Johnson & Johnson$208
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$4,45799%
  • Gifts$531%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,511 in reported general payments places this provider in the 70th percentile of 98 gastroenterology providers in Kansas.

See all gastroenterology providers in Kansas

Medicare billing

Part B allowed, 2024
$240,559
Medicare patients
514
Services billed
6,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$88,550
Mesalamine44$14,370
Ursodiol20$8,830
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates103$6,778
Balsalazide Disodium33$4,730
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl327$4,543
Omeprazole172$3,301
Mesalamine ErMesalamine19$3,296
Pantoprazole Sodium208$2,592
Budesonide DrBudesonide14$2,486
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl123$1,988
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,795
Dicyclomine Hcl32$701
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg11$251
Azathioprine11$242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab$109$1,79511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 98 gastroenterology providers in Kansas.

Other gastroenterology in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →